Barclays
AKBA icon

Barclays’s Akebia Therapeutics AKBA Stock Holding History

Barclays’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,200
Closed -$16K – 5180
2020
Q2 		$16K Hold
1,200
– – ﹤0.01% 5241
2020
Q1 		$9K Sell
1,200
-391
-25% -$3.04K ﹤0.01% 5834
2019
Q4 		$10K Sell
1,591
-4,400
-73% -$20.9K ﹤0.01% 6096
2019
Q3 		$23K Buy
5,991
+400
+7% +$1.71K ﹤0.01% 6176
2019
Q2 		$27K Buy
5,591
+2,500
+81% +$14.2K ﹤0.01% 6329
2019
Q1 		$25K Sell
3,091
-284
-8% -$1.95K ﹤0.01% 6257
2018
Q4 		$19K Buy
+3,375
New +$26.4K ﹤0.01% 5918

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Barclays's AKBA Position: Q1 2026 in Review

Barclays reduced its Akebia Therapeutics (AKBA) stake by 85% in Q1 2026, selling an estimated $1.07M and leaving 142,192 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

Barclays first reported a position in AKBA in Q2 2014 and has held it in 41 quarters since. The position peaked at $3.58M in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Barclays held 142,192 shares of Akebia Therapeutics worth $198K as of Q1 2026.
  • Barclays sold 781,315 Akebia Therapeutics shares in Q1 2026, an estimated $1.07M.
  • Akebia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3688 holding.
  • Barclays first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 41 quarters since.
  • Barclays's Akebia Therapeutics position peaked at $3.58M in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.